<DOC>
	<DOCNO>NCT02211794</DOCNO>
	<brief_summary>Post-market study confirm safety efficacy Journey II BCS knee prosthesis .</brief_summary>
	<brief_title>Journey II BCS EU Observational Trial</brief_title>
	<detailed_description>Multicenter , prospective , observational study collect relevant clinical data 167 subject implant Journey II BCS Knee System . Data eligible subject , provide write informed consent collection cod data record patient 's medical file specially design case report form ( CRF 's ) . Total study duration participant 10 year follow-up visit plan 3 month , 1 year , 2 year , 5 year 10 year post-surgery . An interim analysis describe clinical outcome plan 5 year .</detailed_description>
	<mesh_term>Joint Diseases</mesh_term>
	<mesh_term>Osteoarthritis</mesh_term>
	<criteria>Inclusion Criteria subject require primary total knee arthroplasty Journey II BCS Total Knee System , include patella resurface subject require primary total knee arthroplasty due degenerative joint disease ( primary osteoarthritis , posttraumatic arthritis , avascular necrosis , rheumatoid arthritis ) subject legal age consent , agree consent follow study visit schedule , sign EC approve informed consent form age &gt; 75 year condition may interfere TKA survival outcome ( i.e. , Paget 's Charcot 's disease , vascular insufficiency , muscular atrophy , uncontrolled diabetes , moderate severe renal insufficiency neuromuscular disease ) subject inadequate bone stock support device</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Total Knee Arthroplasty</keyword>
	<keyword>degenerative joint disease</keyword>
</DOC>